Haematological tumours can be cured by haematopoietic stem cell transplantation (HSCT). A European study developed an immunotherapy strategy based on donor T cells to reduce the high morbidity and mortality associated with the HSCT procedure.
A considerable proportion of haematological malignancies are treated with allogeneic HSCT. The success of this therapy is hampered by adverse complications such as graft versus host disease (GvHD) and infections. GvHD occurs when the donor T cells attack the patient’s tissues after transplantation.
Further information: T cells in leukaemia treatment